Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions. Derived from pooled ...

Immunoglobulin replacement therapy (IgRT) represents a pivotal intervention in managing secondary immunodeficiency, a complication arising from treatments or underlying conditions that impair the body ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, ...

MONTREAL — A combination of intravenous immunoglobulin (IVIg) and methylprednisolone (MP) was associated with greater improvement in disability in patients with chronic inflammatory demyelinating ...

Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial evaluating ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...

Treatment with immunoglobulin replacement therapy is often used to boost antibody levels in an effort to reduce infection risk. "Many of the studies supporting the use of immunoglobulins to reduce ...

Neurologist Susan W. Lee, DO, answers common questions about this treatment option for myasthenia gravis. Intravenous immunoglobulin (IVIG) is a pooled collection of antibodies derived from donors’ ...

Please provide your email address to receive an email when new articles are posted on . Glucocorticoids alone demonstrate similar recovery rates as IVIG, or ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

ARLINGTON, Texas--(BUSINESS WIRE)--AOM Infusion, a leading provider of specialty infusion therapy, announced today that it has been selected by GC Biopharma as a limited distribution partner for ...

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...